The Japan cell therapy market was valued at US$ YY million in 2018 and is forecasted to reach US$ YY million by 2029, with a CAGR of 7.1% during the forecast period (2022-2029).
The growth of Japan’s cell therapy market size is driven by several factors such as an increase in the prevalence of chronic diseases, technological advancement in the cell therapy segment and the favourable initiatives by government and private organizations. However, high costs associated with cell therapy is one of the factors restraining the growth of Japan’s cell therapy market.
Download free sample @ https://bit.ly/3Im6wdC
GROWING CASES OF CHRONIC DISEASES
According to World Health Organization (WHO), in Japan chronic diseases accounted for 80% of deaths in 2002. Chronic diseases are increasing three folds in the country due to a large smoking population, a prominent section of the population being old and rising population in the country.
FAVOURABLE GOVERNMENT INITIATIVES
Various studies have shown that cell therapy has the potential in treating several incurable neurological disorders like spinal cord injury, cerebral palsy, Parkinson’s disease, and many more. The remarkable properties of cell therapy in treating various terminal conditions both in vitro and in vivo could be used as the first-line therapy in the future.
Japan is a technologically well off country in all aspects whether its pharmaceuticals, medical devices or cell therapy development.
Since the discovery of human embryonic stem cells, scientists have had high hopes for their use in treating a wider variety of diseases because they are pluripotent. However, the acquisition of human embryonic stem cells from an embryo can cause the destruction of the embryo, thus raising ethical concerns. In 2014, researchers at Brigham and Women’s Hospital, in collaboration with the RIKEN Center for Developmental Biology in Japan, have demonstrated that any mature adult cell has the potential to turn into the equivalent of an embryonic stem cell.
With growing awareness in the industry related to the therapeutic potency of stem cells for effective disease management, there is a rise in the number of clinical trials and successful research studies that aim to validate the therapeutic potential of stem cell-based products. Some of the recent clinical trials are:➢ In August 2019, DiscGenics, Inc., a clinical-stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, announced the first patients have been treated in its Japanese safety study, a clinical trial of IDCT for mild to moderate degenerative disc disease (DDD). IDCT is a homologous, allogeneic, injectable cell therapy that utilizes biomedically engineered progenitor cells, known as Discogenic Cells, that have been derived from intervertebral disc tissue to offer a non-surgical, potentially regenerative solution for the treatment of mild to moderate DDD.
By Cell Source
By Type – Autologous
Autologous cell therapy is beneficial as using the patient’s own stem cells limits immune rejection issues that could occur over time which is one of the primary drivers for market growth.
Favourable government policy by the Japanese government towards faster approval of novel healthcare products are also driving the market for autologous cell therapy in the country such as Japan’s Pharmaceutical and Medical Device Act (PMD). In 2015, HeartSheet by Terumo Co, Tokyo, Japan was approved under the PMD Act. HeartSheet is an autologous skeletal myoblast sheet used to treat severe heart failure because of ischemic heart disease.
View full report @ https://bit.ly/3It0hVe
MERCK & CO. INC.
The company engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. MERCK & CO. INC.
The pharmaceutical segment includes human health pharmaceutical and vaccine products. The animal health segment discovers, develops, manufactures, and markets animal health products such as vaccines, which it sells to veterinarians, distributors, and animal producers.
Company Name: DataM Intelligence
Contact Person: Sai
Email: Send Email
Phone: +1 877 441 4866
Country: United States